Table 31Treatment effects: nasal symptoms–intranasal corticosteroid versus nasal antihistamine

OutcomeaVarianceSS Favors Nasal AH MDNSS Favors/NR Nasal AH MDFavors Neither MD=0NSS Favors/NR INCS MDSS Favors INCS MD
2-Week Outcomes
Congestion
 Carr, 2012 (Trial 1)115 (scale 0-6)SD0.3 (NR)
 Carr, 2012 (Trial 2)115 (scale 0-6)SD0.1 (NR)
 Carr, 2012 (Trial 3)115 (scale 0-6)SD0.1 (NR)
 Ghimire, 2007116 (scale 0-3)0.7 (NR)
 Hampel, 2010117 (scale 0-6)0.11 (NR)
 Kaliner, 2009118 (scale 0-3)a (NSS)
 Newson-Smith, 1997119 (scale 0-3)0.5 (NSS)
 Ratner, 2008121 (scale 0-6)SD0
Rhinorrhea
 Carr, 2012 (Trial 1)115 (scale 0-6)SD0.2 (NR)
 Carr, 2012 (Trial 2)115 (scale 0-6)SD0.3 (NR)
 Carr, 2012 (Trial 3)115 (scale 0-6)SD0.1 (NR)
 Ghimire, 2007116 (scale 0-3)0
 Hampel, 2010117 (scale 0-6)0.28 (NR)
 Kaliner, 2009118 (scale 0-3)a (NSS)
 Newson-Smith, 1997119 (scale 0-3)0.4 (NSS)
 Ratner, 2008121 (scale 0-6)SD0.2 (NR)
Sneezing
 Carr, 2012 (Trial 1)115 (scale 0-6)SD0.2 (NR)
 Carr, 2012 (Trial 2)115 (scale 0-6)SD0.1 (NR)
 Carr, 2012 (Trial 3)115 (scale 0-6)SD0.1 (NR)
 Ghimire, 2007116 (scale 0-3)0.1 (NR)
 Hampel, 2010117 (scale 0-6)0.12 (NR)
 Kaliner, 2009118 (scale 0-3)a (NSS)
 Newson-Smith, 1997119 (scale 0-3)0.4 (NSS)
 Ratner, 2008121 (scale 0-6)SD0
Nasal itch
 Carr, 2012 (Trial 1)115 (scale 0-6)SD0.4 (NR)
 Carr, 2012 (Trial 2)115 (scale 0-6)SD0.1 (NR)
 Carr, 2012 (Trial 3)115 (scale 0-6)SD0.1 (NR)
 Hampel, 2010117 (scale 0-6)0.09 (NR)
 Kaliner, 2009118 (scale 0-3)a (NSS)
 Newson-Smith, 1997119 (scale 0-3)0.4 (NSS)
 Ratner, 2008121 (scale 0-6)SD0.2 (NR)
TNSS
 Carr, 2012 (Trial 1)115 (scale 0-24)SD0.9 (NR)
 Carr, 2012 (Trial 2)115 (scale 0-24)SD0.6 (NR)
 Carr, 2012 (Trial 3)115 (scale 0-24)SD0.6 (NR)
 Hampel, 2010117 (scale 0-24)SD0.59 (NR)
 Kaliner, 2009118 (scale 0-12)a (NSS)
 Pelucchi, 1995120 (scale 0-12)b (NSS)
 Ratner, 2008121 (scale 0-24)SD0.4 (NR)
3-Week Outcomes
Congestion
 Ghimire, 2007116 (scale 0-3)0.5 (NR)
Rhinorrhea
 Ghimire, 2007116 (scale 0-3)0
Sneezing
 Ghimire, 2007116 (scale 0-3)0
TNSS
 Pelucchi, 1995120 (scale 0-12)1.1 (NSS)
4-Week Outcomes
Congestion
 Ghimire, 2007116 (scale 0-3)0.5 (NR)
Rhinorrhea
 Ghimire, 2007116 (scale 0-3)0
Sneezing
 Ghimire, 2007116 (scale 0-3)0
TNSS
 Pelucchi, 1995120 (scale 0-12)1.0 (NSS)
5-Week Outcomes
TNSS
 Pelucchi, 1995120 (scale 0-12)1.4 (NSS)

AH = antihistamine; INCS = intranasal corticosteroid; MD = mean difference between group mean changes from baseline; NR = p-value not reported; NSS = not statistically significant; SS = statistically significant; TNSS = total nasal symptom score.

Variance/confidence interval reported: CI=confidence interval; SD=standard deviation; SE=standard error.

a

Mean difference could not be calculated from reference.

b

Only p-values provided.

From: Results

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.